Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study
PLOS One · 2025
DOI: 10.1371/journal.pone.0333604 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Hayeon Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Korea University, Sejong, Republic of Korea. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Metformin, Glucosides, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Research Foundation of Korea, Korea University.
Abstract (Originalsprache)
The comparative effectiveness of individual sodium–glucose cotransporter-2 inhibitors (SGLT-2is) in preventing ischemic cardiovascular disease (CVD) remains uncertain. Thus, this study compared the incidence of ischemic CVD events in patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin or empagliflozin in combination with metformin. This retrospective cohort study analyzed national claims data from the Korean National Health Insurance Service. Patients with T2DM who received dapagliflozin or empagliflozin, combined with metformin, between 2014 and 2019 were included. The primary outcome was composite ischemic CVD events, defined as myocardial infarction, ischemic stroke, or coronary revascularization. Secondary outcomes included each component of composite ischemic CVD events, unstable angina, and all-cause mortality. Hazard ratios (HRs) and confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusting for covariates in three stepwise models: Model 1 (age and sex), Model 2 (Model 1 variables plus patient characteristics), and Model 3 (Model 2 variables plus clinical parameters). In Model 3, after full adjustment for systolic blood pressure, low-density lipoprotein cholesterol, fasting blood glucose, and serum creatinine, no significant difference was observed in the incidence of composite ischemic CVD events between dapagliflozin and empagliflozin when each was used in combination with metformin (adjusted HR 0.50, 95% CI: 0.24–1.03). Additionally, no significant differences were observed in individual components of composite ischemic CVD events, unstable angina, and all-cause mortality. These real-world findings may help in selecting an SGLT-2is subtype for CVD prevention in Asian patients with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Korea University, Sejong, Republic of Korea.
- Institute of Pharmaceutical Science, Korea University, Sejong, Republic of Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Jeju National University, Jeju, Republic of Korea.
- Education and Research Group for the Convergence of New Approach Methodologies and Innovative Drug Development, Korea University, Sejong, Republic of Korea.
ORCID-Profile: Kyungim Kim
Förderung
- the National Research Foundation of Korea
- Korea University
Zitieren
APA
Kim, H., Lee, S. W., Lim, Y., Han, N., Kang, S., Byun, Y., & Kim, K. (2025). Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0333604
Vancouver
Kim H, Lee SW, Lim Y, Han N, Kang S, Byun Y, et al. Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study. PLOS One. 2025. doi:10.1371/journal.pone.0333604
BibTeX
@article{Kim2025,
author = {Kim, Hayeon and Lee, Seung Won and Lim, Yejee and Han, Nayoung and Kang, Suin and Byun, Youngjoo and Kim, Kyungim},
title = {Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333604}
}
EUVIMED